Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 6/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19953501 | 1.00 | GRM7 (0.61) | GRM7ACEFFAR1KEAP1OPRM1 | |
| SCHEMBL19953548 | 0.91 | GRM7 (0.53) | GRM7ACEFFAR1 | |
| SCHEMBL19960661 | 0.91 | GRM7 (0.53) | GRM7ACEFFAR1 | |
| SCHEMBL19960496 | 0.88 | GRM7 (0.60) | GRM7ACEFFAR1OPRM1OPRL1 | |
| SCHEMBL19960416 | 0.88 | GRM7 (0.60) | GRM7ACEFFAR1OPRM1OPRL1 | |
| SCHEMBL19960417 | 0.84 | GRM7 (0.66) | GRM7ACEFFAR1OPRM1OPRL1 | |
| SCHEMBL19953701 | 0.83 | ACE (0.47) | GRM7ACEFFAR1HDAC4HDAC7 | |
| SCHEMBL19960826 | 0.83 | ACE (0.47) | GRM7ACEFFAR1HDAC4HDAC7 | |
| SCHEMBL20113096 | 0.82 | GRM7 (0.55) | GRM7FFAR1 | |
| SCHEMBL19953697 | 0.82 | ACE (0.46) | GRM7ACEOPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| EP-3541812-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | Takeda Pharmaceutical Company Limited (JP) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018092921-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018092921-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018079862-A1 | MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018079862-A1 | MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | GRM7, GRM2, GRM1 | GRM7 1/4885ACE 3661/4885FFAR1 159/4885 |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | GRM7, GRM2, GRM1 | GRM7 1/4885ACE 3661/4885FFAR1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.